Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 11, 2011, Pages 5172-5177

  Damle, Bharat ^a   Varma, Manthena V ^a   Wood, Nolan ^b,c  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c Takeda Global Research and Development Centre (Europe) Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; FLUCONAZOLE; VORICONAZOLE;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; MAXIMUM PLASMA CONCENTRATION; MOLECULAR INTERACTION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIMULATION; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; BODY MASS INDEX; CROSS-OVER STUDIES; FLUCONAZOLE; HUMANS; MALE; MIDDLE AGED; PYRIMIDINES; TRIAZOLES; YOUNG ADULT;

EID: 80054680414     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00423-11     Document Type: Article

References (34)

1. Andrews, E., et al. 2008. Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects. Br. J. Pharmacol. 65:531-539. (Pubitemid 351365140)
2. European Medicines Agency. 2009. Vfend: EPAR-product information (last updated January 2011). European Medicines Agency, London, United Kingdom. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 000387/human-med-001135.jsp&murl=menus/medicines/medicines. jsp&mid-WC0b01ac058001d125. Accessed 11 March 2011.
3. Hyland, R., B. C. Jones, and D. A. Smith. 2003. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab. Dispos. 31:540-547. (Pubitemid 36444162)
4. Iatsimirskaia, E., et al. 1997. Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. Clin. Pharmacol. Ther. 61:554-562. (Pubitemid 27261759)
5. Imhof, A., D. J. Schaer, U. Schanz, and U. Schwarz. 2006. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med. Wkly. 136:739-742. (Pubitemid 46032197)
6. Ko, J.-W., N. Sukhova, D. Thacker, P. Chen, and D. A. Flockhart. 1997. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab. Dispos. 25:853-862. (Pubitemid 27318604)
7. Lazarus, H. M., J. L. Blumer, S. Yanovich, H. Schlamm, and A. Romero. 2002. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J. Clin. Pharmacol. 42:395-402. (Pubitemid 34259773)
8. Maurice, M., et al. 1992. Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J. 6:752-758.
9. Murayama, N., N. Imai, T. Nakane, M. Shimizu, and H. Yamazaki. 2007. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem. Pharmacol. 73:2020-2026. (Pubitemid 46677908)
10. Nielsen, T. L., B. B. Rasmussen, J. P. Flinois, P. Beaune, and K. Brosen. 1999. In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes. J. Pharmacol. Exp. Ther. 289:31-37. (Pubitemid 29156009)
11. Nivoix, Y., et al. 2008. The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin. Pharmacokinet. 47:779-792.
12. Niwa, T., T. Shiraga, and A. Takagi. 2005. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol. Pharm. Bull. 28:1805-1808. (Pubitemid 41324160)
13. Pascual, A., et al. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46:201-211. (Pubitemid 351269158)
14. Pemán, J., et al. 2006. Voriconazole in the management of nosocomial invasive fungal infections. Ther. Clin. Risk Manag. 2:129-158. (Pubitemid 43950051)
15. Pfaller, M. A., S. A. Messer, R. J. Hollis, R. N. Jones, and D. J. Diekema. 2002. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob. Agents Chemother. 46:1723-1727. (Pubitemid 34535188)
16. Pfizer Inc. 2010. Diflucan - U.S. prescribing information (revised January 2010). Pfizer Inc., New York, NY.
17. Pfizer Inc. 2010. Vfend - U.S. prescribing information (revised June 2010). Pfizer Inc., New York, NY.
18. Prentice, A. G., et al. 2008. Guidelines on the management of invasive fungal infection during therapy for haematological malignancy. BCSH guidelines home page. Pfizer Inc., New York, NY.
19. Purkins, L., et al. 2002. Pharmacokinetics and safety of voriconazole following intravenous-to oral-dose escalation regimens. Antimicrob. Agents Chemother. 46:2546-2553. (Pubitemid 34793462)
20. Purkins, L., N. Wood, K. Greenhalgh, M. J. Allen, and S. D. Oliver. 2003. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br. J. Clin. Pharmacol. 56(Suppl.)1:10-16.
21. Ruhnke, M., A. Schmidt-Westhausen, and M. Trautmann. 1997. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible andresistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 41:575-577. (Pubitemid 27098406)
22. Scholz, I., et al. 2009. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br. J. Clin. Pharmacol. 68:906-915.
23. Segal, B. H., and W. J. Steinbach. 2007. Combination antifungals: an update. Expert Rev. Anti Infect. Ther. 5:883-892. (Pubitemid 47610950)
24. Tan, K., N. Brayshaw, K. Tomaszewski, P. Troke, and N. Wood. 2006. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J. Clin. Pharmacol. 46:235-243. (Pubitemid 43146453)
25. Theuretzbacher, U., F. Ihle, and H. Derendorf. 2006. Pharmacokinetic/ pharmacodynamic profile of voriconazole. Clin. Pharmacokinet. 45:649-663. (Pubitemid 43990568)
26. Thursky, K. A., et al. 2008. Recommendations for the treatment of established fungal infections. Intern. Med. J. 38:496-520. (Pubitemid 351904422)
27. Venkatakrishnan, K., L. L. von Moltke, and D. J. Greenblatt. 2000. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin. Pharmacokinet. 38:111-180. (Pubitemid 30122116)
28. Walsh, T. J., et al. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360. (Pubitemid 351265310)
29. Wang, G., et al. 2009. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur. J. Clin. Pharmacol. 65:281-285.
30. Weiss, J., et al. 2009. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J. Clin. Pharmacol. 49:196-204.
31. Wienkers, L. C., et al. 1996. Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metab. Dispos. 24:610-614. (Pubitemid 26146703)
32. Wood, et al. 2003. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br. J. Clin. Pharmacol. 56(Suppl. 1):56-61. (Pubitemid 37491735)
33. Xiao, Z.-S., et al. 1997. Differences in the incidence of the CYP2C19 polymorphism affecting the S-methenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J. Pharmacol. Exp. Ther. 281:604-609. (Pubitemid 27203121)
34. Yamazaki, H., M. Nakamoto, M. Shimizu, N. Murayama, and T. Niwa. 2010. Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles. Br. J. Clin. Pharmacol. 69:593-597.